Median progression free survival ( PFS ) for 120 patients allocated XP plus simvastatin was 5.2 months ( 95 % confidence interval ( CI ) 4.3-6 .1 ) compared with 4.63 months ( 95 % CI 3.5-5 .7 ) for 124 patients who were allocated to XP plus placebo ( hazard ratio 0.930 , 95 % CI 0.684-1 .264 ; p = 0.642 ) .